FIG. 1.

ZLN005 increases expression of the PGC-1α gene in L6 myotubes. L6 myotubes were differentiated for 4–6 days. A: The structure of ZLN005 (molecular weight 250.3). B: Dose-dependent effect of ZLN005 on PGC-1α mRNA levels. L6 myotubes were treated for 24 h with different doses of ZLN005 or 1 mmol/L AICAR as a positive control. C: Time course of ZLN005 on PGC-1α mRNA levels. D: Effect of ZLN005 (10 μmol/L) on relative mRNA levels. E: Dose-dependent effect of ZLN005 on glucose uptake over 24 h. Insulin (100 nmol/L) was added in the last 30 min. F: Dose-dependent effect of ZLN005 on palmitic acid oxidation over 24 h. Radioactive medium containing compounds of interest was changed at the start of the last 4 h. Two millimolar AICAR was also added in the last 4 h. *P < 0.05, **P < 0.01 compared with DMSO.